[Drug treatment of migraine attacks. Pharmacological considerations].
In the 1990s, the Decade of the Brain, significant progress has been made in our understanding of the pathophysiological events that take place during a migraine attack. Simultaneously, a big step forward has been made as regards drug therapy. The development of the 5-Hydroxy Tryptamine ID (5HT1D)-agonist sumatriptan has changed the lives of many migraine sufferers. This review describes attack management with analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), ergotamines and sumatriptan. Adverse events associated with ergotamines and use of sumatriptan are focused upon, with special attention to the pharmacokinetic and pharmacodynamic aspects of both these drugs. Sumatriptan has both vascular and neurogenic effects, both of which may be necessary for a good clinical outcome.
Salvesen
R
R
Neurologisk avdeling, Nordland Sentralsykehus, Bodø.
D000700:Analgesics / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D004879:Ergotamines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D018170:Sumatriptan / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology
D000700:Analgesics; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004879:Ergotamines; D012702:Serotonin Antagonists; D018170:Sumatriptan